Repositorio de producción científica de la Universidad de Sevilla

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results

 

Advanced Search
 
Opened Access Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Cites

Show item statistics
Icon
Export to
Author: Argüelles Arias, Federico
Guerra Veloz, María
Perea Amarillo, Raúl
Vilches Arenas, Ángel
Castro Laria, Luisa
Romero Gómez, Manuel
Department: Universidad de Sevilla. Departamento de Medicina
Date: 2017
Document type: Article
Abstract: Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological the...
[See more]
Size: 219.6Kb
Format: PDF

Swithching

URI: https://hdl.handle.net/11441/83530

DOI: 10.1097/MEG.0000000000000953

This work is under a Creative Commons License: 
Attribution-NonCommercial-NoDerivatives 4.0 Internacional

This item appears in the following Collection(s)